The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience

<div>Remission at 6 months separated by clinical decision following infliximab therapeutic drug monitoring in inflammatory bowel disease patients with concerns for loss of response.</div>

Canadian Journal of Gastroenterology and Hepatology

fig4

Figure 4

Figure 4: The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience 

Figure 4 | The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience 